Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress [Yahoo! Finance]
Zenas BioPharma, Inc. (ZBIO)
Company Research
Source: Yahoo! Finance
Zenas BioPharma started trading on the NASDAQ in September 2024. The company closed an upsized initial public offering of 15.22 million shares at $17 per share, raising approximately $258.7 million in gross proceeds The company's lead program obexelimab concluded enrollment in the Phase 3 INDIGO trial for immunoglobulin-G4-Related Disease (IgG4-RD). Topline data is expected by the end of 2025 The company also initiated the Phase 2 MoonStone trial for Relapsing Multiple Sclerosis (MS) and the Phase 2 SunStone trial for Systemic Lupus Erythematosus (SLE). Also Read: PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July 12-week primary endpoint results
Read more
Impact Snapshot
Event Time:
ZBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZBIO alerts
High impacting Zenas BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
ZBIO
News
- Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire
- ZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIOPR Newswire
- ZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIOPR Newswire
- Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire
- ZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIOPR Newswire
ZBIO
Sec Filings
- 3/21/25 - Form 3
- 3/11/25 - Form S-8
- 3/11/25 - Form 10-K
- ZBIO's page on the SEC website